Residency · Residency · Neurology

Obstructive Sleep Apnea and Its Neurological Consequences

Introduction

Obstructive sleep apnea (OSA) is the most prevalent sleep-related breathing disorder, affecting an estimated 15-30% of men and 10-15% of women. Beyond its well-known cardiovascular effects, OSA has substantial neurological consequences including increased stroke risk, cognitive impairment, and exacerbation of neurodegenerative disease. Neurologists must be proficient in recognizing OSA and understanding its impact on neurological health.

Pathophysiology

Upper airway collapse during sleep results from reduced pharyngeal muscle tone, anatomical narrowing, or both. Each obstructive event causes oxygen desaturation, hypercapnia, intrathoracic pressure swings, and sympathetic activation. Events are terminated by cortical arousal, which fragments sleep architecture. Intermittent hypoxia is the primary mediator of end-organ damage, triggering oxidative stress, systemic inflammation, and endothelial dysfunction. Recurrent arousals eliminate restorative slow-wave and REM sleep, contributing to excessive daytime sleepiness and cognitive dysfunction.

Clinical Presentation

Nocturnal Symptoms

Nocturnal symptoms include loud habitual snoring with witnessed apneas, gasping, choking, or snorting during sleep, restless sleep with frequent awakenings, and nocturia.

Daytime Symptoms

Excessive daytime sleepiness is the hallmark daytime symptom, assessed with the Epworth Sleepiness Scale where a score greater than 10 is abnormal. Morning headaches, impaired concentration and memory difficulties, mood disturbances including irritability and depression, and decreased libido are all common.

Risk Factors

Major risk factors include obesity (BMI greater than 30 kg/m^2), male sex, and increasing age. Craniofacial features predisposing to OSA include retrognathia, macroglossia, large tonsils, and a short wide neck. Central obesity and neck circumference greater than 17 inches in men or greater than 16 inches in women increase risk. The STOP-Bang questionnaire is a useful screening tool, with a score of 5 or greater indicating high risk.

Diagnosis

Polysomnography (PSG)

Polysomnography is the gold standard for diagnosis. It measures airflow via nasal pressure transducer and thermistor, respiratory effort via thoracic and abdominal belts, oxygen saturation, EEG, EMG, and EOG. An apnea is defined as cessation of airflow for 10 seconds or more. A hypopnea is a 30% or greater reduction in airflow for 10 seconds or more with 3% oxygen desaturation or arousal. The Apnea-Hypopnea Index (AHI) quantifies severity: mild OSA is AHI 5-14, moderate is AHI 15-29, and severe is AHI 30 or greater.

Home Sleep Apnea Testing (HSAT)

Home sleep apnea testing is acceptable for diagnosis in patients with high pretest probability and no significant comorbidities. It measures airflow, respiratory effort, and oximetry without EEG, and may underestimate severity because total sleep time is not measured.

Neurological Consequences of OSA

Stroke and Cerebrovascular Disease

OSA is an independent risk factor for ischemic stroke with a hazard ratio of approximately 2-3 for severe OSA. Mechanisms include hypertension, atrial fibrillation, paradoxical embolism via patent foramen ovale, hypercoagulability, and endothelial dysfunction. OSA is highly prevalent in stroke patients at 50-75% and worsens post-stroke outcomes. Screening for OSA should be part of the post-stroke workup.

Cognitive Impairment

OSA causes deficits in attention, executive function, visuospatial processing, and memory. Chronic intermittent hypoxia damages hippocampal neurons and the prefrontal cortex. OSA may accelerate cognitive decline in older adults and increase the risk of developing Alzheimer disease. Impaired glymphatic clearance of amyloid-beta during fragmented sleep is a proposed mechanism linking these conditions.

Epilepsy

OSA is more prevalent in patients with epilepsy than in the general population. Untreated OSA increases seizure frequency through sleep deprivation and hypoxia. Treatment of OSA with CPAP can improve seizure control and reduce antiseizure medication requirements.

Headache

Morning headaches are reported by 15-50% of OSA patients. OSA may trigger and exacerbate migraine, cluster headache, and hypnic headache. CPAP treatment often improves headache frequency and severity.

Neuropathy and Neuromuscular Disease

OSA is common in patients with neuromuscular disorders such as myotonic dystrophy, ALS, and myasthenia gravis due to upper airway and respiratory muscle weakness. Central and obstructive events may coexist in these populations. Non-invasive ventilation with BiPAP may be preferred over CPAP in patients with neuromuscular respiratory weakness.

Treatment

Continuous Positive Airway Pressure (CPAP)

CPAP is the first-line therapy for moderate to severe OSA. It functions as a pneumatic splint to maintain upper airway patency during sleep. CPAP effectively reduces AHI, improves oxygenation, reduces daytime sleepiness, and lowers blood pressure. Adherence is the major challenge, with approximately 50% of patients not using CPAP regularly (defined as 4 or more hours per night on 70% or more of nights). Strategies to improve adherence include proper mask fitting, humidification, behavioral interventions, and auto-titrating devices.

Oral Appliances

Mandibular advancement devices are indicated for mild-to-moderate OSA or CPAP-intolerant patients. They protrude the mandible forward to enlarge the retropalatal and retroglossal airway.

Surgical and Procedural Options

Uvulopalatopharyngoplasty (UPPP) has variable success rates. Hypoglossal nerve stimulation (Inspire) is appropriate for moderate-to-severe OSA with CPAP failure and BMI less than 32. Maxillomandibular advancement is the most effective surgical option but more invasive. Bariatric surgery benefits obese patients when weight is the primary contributor.

Positional Therapy and Weight Loss

Supine-predominant OSA may respond to positional therapy using devices that prevent supine sleeping. Weight loss of 10-15% can substantially reduce AHI in obese patients.

Clinical Pearls

Every stroke patient should be screened for OSA, as it is present in the majority and represents a modifiable risk factor for recurrent stroke. OSA-related cognitive impairment may be partially reversible with consistent CPAP use, making early diagnosis and treatment essential. CPAP adherence, not just prescription, determines clinical benefit, so barriers to adherence must be addressed proactively. In patients with drug-resistant epilepsy, screening for OSA should be considered as untreated sleep apnea may be contributing to poor seizure control. Neuromuscular disease patients with sleep-disordered breathing often require BiPAP rather than CPAP due to concomitant hypoventilation.

References

1. Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69(7):841-858.
2. Leng Y, McEvoy CT, Allen IE, Yaffe K. Association of sleep-disordered breathing with cognitive function and risk of cognitive impairment: a systematic review and meta-analysis. JAMA Neurol. 2017;74(10):1237-1245.
3. Brown DL, Shafie-Khorassani F, Kim S, et al. Sleep-disordered breathing is associated with recurrent ischemic stroke. Stroke. 2019;50(3):571-576.
4. Patil SP, Ayappa IA, Caples SM, et al. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2019;15(2):335-343.

For the intern

At 3am, if a patient with known OSA presents with acute neurological symptoms (stroke, seizure, severe headache), treat the acute event first—OSA management is not urgent. Obtain urgent imaging, labs, and consult as appropriate. Document witnessed apneas or snoring in the history as this strengthens the case for formal sleep study after stabilization. If a stable patient mentions poor CPAP adherence and worsening symptoms, this conversation can wait until morning rounds. Focus overnight efforts on life-threatening presentations; OSA screening and treatment optimization are outpatient priorities.

Common pitfalls

• Dismissing OSA in non-obese patients: While obesity is the strongest risk factor, approximately 30% of OSA patients have BMI less than 30. Craniofacial anatomy (retrognathia, macroglossia) and neck circumference matter. Always consider OSA in stroke or cognitive impairment workups regardless of body habitus.

• Assuming CPAP prescription equals treatment: Adherence rates hover around 50%. Asking "Do you have a CPAP?" is insufficient—ask "How many hours per night do you actually use it?" Non-adherence explains persistent symptoms despite "treatment."

• Overlooking OSA in neuromuscular patients: These patients may need BiPAP rather than CPAP due to hypoventilation. Standard CPAP provides inspiratory support only; BiPAP delivers both inspiratory and expiratory pressure assistance for weakened respiratory muscles.

• Missing the stroke-OSA connection: Half to three-quarters of stroke patients have OSA. Screen every ischemic stroke patient—it's a modifiable recurrent stroke risk factor often more impactful than statin adjustment.

<image> Create a simple clinical decision algorithm with three main pathways flowing from top to bottom:

Top panel: Box labeled "Patient with suspected OSA" with arrows pointing to three assessment boxes below.

Middle panel - Left pathway: "High-risk features present?" (obesity, male, age >50, neck circumference >17"/16", witnessed apneas, HTN, stroke history). Arrow down to "Formal PSG or HSAT" box, then arrow to "AHI ≥15 or symptomatic AHI 5-14" leading to "Initiate CPAP" box.

Middle panel - Center pathway: "Neurological patient?" (stroke, TIA, cognitive impairment, refractory epilepsy, morning headaches). Arrow directly to "Priority OSA screening - strongly recommend PSG" box, then same pathway joining left to CPAP initiation.

Middle panel - Right pathway: "Neuromuscular disease?" (ALS, myasthenia, myotonic dystrophy). Arrow to "Consider BiPAP over CPAP" box with note "(hypoventilation likely)".

Bottom panel: All pathways converge to final box: "Adherence monitoring essential - check usage hours, troubleshoot barriers at follow-up"

Use different colored boxes for each pathway (blue for general OSA, red for neuro priority, green for neuromuscular). Keep text minimal within boxes, use clear directional arrows. </image>

Read this lecture as Markdown